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Abstract
Rationale Recently, we showed that 2-bromoterguride acted
as a dopamine D2 receptor partial agonist, a serotonin 5-HT2A
and α2C-adrenergic receptor antagonist, and exhibited
antidopaminergic efficacy in amphetamine-induced locomo-
tion (AIL) in rats without inducing catalepsy.
Objective To extend our knowledge on the antipsychotic ef-
fects of 2-bromoterguride, we used convergent preclinical an-
imal models and tests; i.e., conditioned avoidance response
(CAR), predictive of antipsychotic-like effects; Fos protein
expression, a molecular marker for (atypical) antipsychotic
activity; wet dog shake behavior, a test for the in vivo effects
of drugs acting on central 5-HT2A receptors; and investigated
metabolic changes as a common side effect of atypical anti-
psychotic drugs (APDs).
Results Acute treatment with 2-bromoterguride (0.1 and
0.3 mg/kg) decreased the CAR at 30, 90, and 270 min post-
injection in rats without inducing escape failures at any time.
Fos protein expression, as shown by Western blotting, was en-
hanced by 2-bromoterguride in the nucleus accumbens (NAc),
the dorsolateral striatum (dStr), and the medial prefrontal cortex
(mPFC). (±)-2,5-Dimethoxy-4-iodoamphetamine (DOI)-in-
duced wet dog shakes in rats were reduced by 2-
bromoterguride. Chronic treatment with 2-bromoterguride did
not affect metabolic parameters such as body weight
development and body fat composition as well as behavioral
parameters such as food intake and locomotor activity.
Conclusions Our data suggest that 2-bromoterguride is a
promising candidate in the treatment of schizophrenia due to
its atypical antipsychotic-like activity and its inability to in-
duce weight gain.
Keywords DopamineD2 receptor partial agonist .Wet dog
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Weight gain . Antipsychotic
Introduction
The majority of patients with schizophrenia are treated
with typical or atypical antipsychotic drugs (APDs)
(Leucht et al. 2009, 2013). Typical APDs such as halo-
peridol possess high antagonist potency at dopamine D2
receptors but carry substantial risk to induce extrapyrami-
dal side effects (EPS) and increased release of prolactin
(Meltzer 2013). Atypical APDs with a clozapine-like pro-
file interact with varying affinities at D2, 5-HT2A, 5-HT2C,
and many other monoamine receptors including α1- and
α2-adrenoceptor subtypes and histamine H1 receptors
(Kroeze et al. 2003; Leucht et al. 2009; Meltzer et al.
2012; Roth et al. 2004; Schoemaker et al. 1997). The
key feature that distinguishes typical from atypical
APDs is that the latter produce fewer EPS than the first
(Meltzer 2013). However, atypical APDs cause consider-
able weight gain, which may be based, at least in part, on
the antagonist properties of these drugs at histamine H1
and 5-HT2C receptors (Kroeze et al. 2003; Roth et al.
2004).
The advent of aripiprazole, a D2 receptor partial agonist of
moderate intrinsic activity, has generated a new treatment
* Jan Brosda
jan.brosda@fu-berlin.de
1 Institute of Pharmacology and Toxicology, School of Veterinary
Medicine, Freie Universität Berlin, 14195 Berlin, Germany




option in schizophrenia (DeLeon et al. 2004). D2 receptor
partial agonists may induce a desirable stabilization of dopa-
minergic transmission insofar as they decrease transmission
postsynaptically in the mesolimbic system and increase trans-
mission at the mesocortical level (Lieberman 2004; Stahl
2001). Aripiprazole does not cause EPS (Leucht et al. 2013);
like other atypical APDs, it shows high affinity for multiple 5-
HT receptors and other central neuroreceptors (Kroeze et al.
2003).
We recently showed that 2-bromoterguride, an ergot
derivative, mechanistically mimicked aripiprazole as a
D2 receptor partial agonist (Jantschak et al. 2013).
However, compared with aripiprazole, 2-bromoterguride
exhibited much higher affinity for 5-HT2A receptors and
α2C-adrenoceptors and much lower affinity for hista-
mine H1 receptors (Jantschak et al. 2013). Preclinical
tests using rats confirmed that the multifunctional drug
2-bromoterguride had antidopaminergic activity as dem-
onstrated by the inhibition of amphetamine-induced lo-
comotion (AIL) and exhibited low EPS liability as
shown by the failure to produce catalepsy. The in vivo
observations in conjunction with its broad neuroreceptor
binding profile suggest that 2-bromoterguride may be
classified as an atypical APD.
The aim of the present study was to extend our knowl-
edge on the antipsychotic effects of 2-bromoterguride. We
examined whether 2-bromoterguride might inhibit the
conditioned avoidance response (CAR), a widely accepted
screening tool in rats with high predictive validity that has
shown particular sensitivity for detection of potential an-
tipsychotic activity (Wadenberg 2010). It is well docu-
mented that APDs alter Fos expression in nucleus accum-
bens (NAc), dorsolateral striatum (dStr), and medial pre-
frontal cortex (mPFC) (Robertson et al. 1994; Sumner
et al. 2004). Therefore, we measured 2-bromoterguride-
induced Fos protein expression in these brain regions with
special focus on the effects in the mPFC because a Fos
enhancement in this region can be used to identify atypi-
cal APDs (Robertson and Fibiger 1996). To substantiate
the 5-HT2A recep to r an tagon i s t po tency of 2-
bromoterguride in vivo, it seemed reasonable to find out
whether the drug was able to reduce (±)-2,5-dimethoxy-4-
iodoamphetamine (DOI)-induced wet dog shakes in rats, a
test for drugs acting on central 5-HT2A receptors
(Schreiber et al. 1995). As mentioned above, atypical
APDs can induce weight gain. Therefore, we analyzed
the effects of prolonged 2-bromoterguride administration
on food intake, weight gain, and body fat composition, as
well as on food and water consumption. Together with the
preclinical tests of our previous study, AIL and catalepsy
(see Jantschak et al. 2013), we conclude that 2-
bromoterguride has atypical antipsychotic properties with-
out metabolic side effects such as weight gain.
Materials and methods
Animals
All experiments were performed in accordancewith the guide-
lines of the German Animal Protection Law and approved by
the Berlin State Authority (BLandesamt für Gesundheit und
Soziales^). A total of 163 naïve male (acute experiments) and
female (chronic experiment) Sprague-Dawley rats (Élevage
Janvier, Le Genest Isle, France) at an age of 10–13 weeks
were used. The animals were housed in groups of two to three
in type IV open-top polycarbonate cages (Ehret ,
Emmendingen, Germany) with dust-free hardwood bedding
(Hygienic Animal Bedding; J. Rettenmaier & Söhne,
Rosenberg, Germany) under standard conditions (room tem-
perature, 22 ± 2 °C; relative humidity 55 ± 10 %) on a 12-h
light-dark schedule (lights on at 6:00 A.M.). Home cages were
enriched by paper tissues and metal tubes as hiding places.
Rats had free access to standard laboratory chow (ssniff,
Soest, Germany) and tap water and were handled and weighed
regularly. Once weekly, the home cages were cleaned and
equipped with new bedding by a professional animal keeper.
Animals were free of pathogens according to Federation for
Laboratory Animal Science (FELASA) recommendations.
Drugs
2-Bromoterguride (Alfarma sro, Cernosice, Czech Republic)
and olanzapine (Sigma-Aldrich, Steinheim, Germany) were
suspended in 15 % Cremophor® EL (Sigma-Aldrich,
Steinheim, Germany). Aripiprazole (Toronto Research
Chemicals, Toronto, Canada) was dissolved in N,N-
dimethylformamide (30 %) blended with acetic acid (1 %).
(±)-2,5-Dimethoxy-4-iodoamphetamine hydrochloride (DOI;
Sigma-Aldrich, Steinheim, Germany), ketanserin tartrate, and
haloperidol (Janssen Pharmaceuticals, Beerse, Belgium) were
dissolved in 0.9 % saline. All drug solutions were freshly
prepared before being injected intraperitoneally (i.p.; injection
volume 1 ml/kg body weight).
Conditioned avoidance response
Male rats were trained and tested in two computer-assisted,
two-way active avoidance shuttle boxes (Med Associates Inc.,
St. Albans, USA), which were enclosed by MDF sound-
attenuating cubicles and equipped with stimulus lights, tone
generators, and grid floors. Each shuttle box consisted of two
compartments of equal size separated by a partition with an
aperture, which allowed the rats to move freely between the
compartments. The positions of the animals were tracked by
eight infrared photobeams. Each session (training, drug-free
pre-test, drug-test) started with a 3-min habituation period, in
which no stimuli presentation occurred, followed by 30 trials.
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Upon presentation of a white noise (76 dB) and light as con-
ditioned stimuli (CS), rats needed to move from one compart-
ment into the other within 10 s to avoid the unconditioned
stimulus (UCS), which was presented for 20 s as an intermit-
tent electric shock in the grid floor (0.3mA; interval 2 s; single
shock duration 0.5 s). Moving from one compartment to the
other one within the first 10 s (response to CS) was recorded
as avoidance, and a change as a response to the UCS was
recorded as an escape. Escape failures were recorded if an
animal failed to respond to the CS and USC within the trial
duration of 30 s. Inter-trial intervals randomly varied between
10 and 30 s. Rats were daily trained until they met the test
criterion (≥80 % avoidances) on two consecutive days. The
next day, a drug-free pre-test was performed. Subsequently,
the animals were injected with 2-bromoterguride (0.1 and
0.3 mg/kg), haloperidol (0.05 and 0.1 mg/kg), aripiprazole
(1 and 3 mg/kg), or the respective vehicle. The CAR was
evaluated 30, 90, and 270 min and 24 h post-injection as
percent avoidance compared to percent avoidance of the pre-
test and percent avoidance of the control group, respectively.
The doses for aripiprazole and haloperidol were determined
by conducting pilot studies. Each compound was tested in one
treatment group. The animals of the three treatment groups
were tested repeatedly in a pseudorandom order serving as
their own controls (wash-out period of at least 4 days).
Neuronal Fos expression
Male rats were transferred within their home cages to a sound-
proof red lighted dark-room for 2 days. During this period,
they were habituated to injections of saline. On day 3, rats
were injected with 2-bromoterguride (0.1 and 0.3 mg/kg),
haloperidol (0.5 mg/kg), or vehicle (15 % Cremophor® EL).
The dose of haloperidol was determined by conducting a pilot
study. Two hours later, animals were sacrificed by decapita-
tion and brains rapidly removed from the skull. Brain areas
were dissected on a cold plate. The following tissue samples
were weighed and shock frozen in liquid nitrogen: mPFC,
NAc, and dStr (Heffner et al. 1980).
Expression of Fos and β-actin in brain homogenates were
studied by Western blotting using the following primary anti-
bodies: rabbit anti-Fos (1:2000) and rabbit anti-β-actin as
loading control (1:20,000; New England BioLabs, Frankfurt
a. M., Germany). Bands were detected by probing with a
horseradish peroxidase-conjugated goat anti-rabbit secondary
antibody (1:10,000; Cell Signaling Technology, Leiden,
The Netherlands). Visualization was achieved by chemi-
luminescence with ECL Prime Western Blotting
Detec t ion Reagent (Amersham, Braunschweig ,
Germany) on Amersham Hyperfilm (GE Healthcare
Limited, Little Chalfont, UK). Quantification of bands
was obtained by digital image analysis using National
Institutes of Health Image software (http://rsb.info.nih.
gov/ij/download.html).
Antagonism of DOI-induced wet dog shakes
The experiments were conducted in two glass cuboids (29 ×
22 × 39 cm) of which the grounds were coated with bedding
material. Male rats were given an injection of either 2-
bromoterguride (0.1 or 0.3 mg/kg), aripiprazole (3 mg/kg),
ketanserin (1 mg/kg), or vehicle (15 % Cremophor® EL).
After 30 min, animals were injected with DOI (2 mg/kg) and
vehicle, respectively. Subsequently, the behavior of the animals
was monitored and recorded (Canon HG10 HD-Camcorder;
Canon, Krefeld, Germany) for 30 min. A trained observer of
rat behavior determined the number of wet dog shakes.
Body weight development, body fat composition, food
intake, locomotor activity, and cataleptic behavior
Female rats were used as they exhibit a more robust weight
gain following atypical APD treatment compared to males
(Choi et al. 2007; Davey et al. 2012). However, in female rats,
clozapine does not increase weight gain mandatorily but does
increase visceral fat tissue (Cooper et al. 2008). Therefore, we
used a comprehensive approach by investigating the effects of
2-bromoterguride on body fat composition and body weight
development with olanzapine (instead of clozapine) as a pos-
itive control. Animals were matched into four different treat-
ment groups based on their body weight. Rats were injected
B.I.D. (first injection between 9:00 and 10:00 A.M.; second
injection between 4:00 and 5:00 P.M.) with 2-bromoterguride
(0.1 and 0.3 mg/kg), olanzapine (2 mg/kg), or vehicle (15 %
Cremophor® EL) for 21 days. Body weight, food and water
intake were measured daily prior to the first injection. Weight
gain (%) was calculated in relation to body weight of day 0.
The amount of food and water consumed was calculated in
grams or milliliters per cage (n = 2) in relation to body weight.
On day 22, rats were deeply anaesthetized with chloral hy-
drate (720 mg/kg; Sigma-Aldrich, Steinheim, Germany) and
visceral (gonadal and retroperitoneal), subcutaneous (ingui-
nal), and brown fat tissue (interscapular) were dissected and
weighed by a trained experimenter. Tissue weights were cal-
culated in relation to body weight. In order to compare the
effect of acute versus prolonged 2-bromoterguride treatment
on behavior, we analyzed locomotor activity in the open field
(day 14; distance traveled (cm)) and cataleptic behavior
(day 20; bar and grid test) as described previously
(Jantschak et al. 2013).
Data presentation and analysis
Data were analyzed and presented using SigmaPlot 11 (Systat
Software, Erkrath, Germany). The following tests were used:
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one-way analysis of variance (ANOVA) (Fos expression, wet
dog shakes, body fat composition, locomotor activity) and
two-way repeated measures (RM) ANOVA (treatment × time)
(CAR, body weight development, food intake) followed by
Holm-Sidak t tests. Data of escape failures and cataleptic be-
havior were not normally distributed (tested with the Shapiro-
Wilk method) and analyzed with non-parametric Friedman
one-way RM ANOVA and Kruskal-Wallis one-way
ANOVA followed by Dunn’s method, respectively. P values
<0.05 were considered to be significant. Data are presented as
mean values ± standard error of the means (SEM).
Results
Conditioned avoidance response
2-Bromoterguride, haloperidol, and aripiprazole inhibited CAR
in a dose-dependent manner (Fig. 1). 2-Bromoterguride: signif-
icant effects for the factors treatment (F(2,88) = 12.7, P < 0.001),
time (F(4,88) = 23.3, P < 0.001), and for the interaction of the
factors (F(8,88) = 4.7, P < 0.001) were observed. Both doses of
2-bromoterguride (0.1 and 0.3 mg/kg) decreased the CAR at
30, 90, and 270 min post-injection compared to pre-tests
(P < 0.01) and controls (P < 0.001) without inducing escape
failures at any time (Fig. 1a). Haloperidol: a two-way RM
ANOVA showed significant effects for the factors treatment
(F(2,72) = 16.3, P < 0.001), time (F(4,72) = 23.6, P < 0.001), and
for the interaction of the factors (F(8,72) = 9.1, P < 0.001).
Haloperidol (0.1 mg/kg) decreased the CAR at 30 min post-
injection, whereas 0.05 and 0.1 mg/kg haloperidol showed this
effect at 90 and 270 min after administration compared to pre-
tests (P < 0.001) and controls (P < 0.01) without inducing any
escape failures (Fig. 1b). Aripiprazole: significant effects for the
factors treatment (F(2,80) = 38.5, P < 0.001), time (F(4,80) = 49.1,
P < 0.001), and for the interaction of the factors (F(8,80) = 12.9,
P < 0.001) were revealed. Both doses of aripiprazole (1 and
3 mg/kg) decreased the CAR at 30, 90, and 270 min post-
injection compared to pre-tests (P < 0.001) and controls
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Fig. 1 Effects of 2-
bromoterguride (0.1 and
0.3 mg/kg; a), haloperidol (0.05
and 0.1 mg/kg; b), or aripiprazole
(1 and 3 mg/kg; c) on percentage
conditioned avoidance response
at 30, 90, and 270 min after
injection. Data are expressed as
mean ± SEM of 12 (2-
bromoterguride, aripiprazole) or
10 male rats (haloperidol).
*P < 0.05 vs. vehicle. 2-BT 2-
bromoterguride, ARI aripiprazole,
HAL haloperidol, VEH vehicle
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failures 30 min (escape failures–vehicle 0 ± 0, aripiprazole 3.2
± 1.4; χ2 = 13.6, P < 0.01, df = 2) and 90 min (escape failures–
vehicle 0 ± 0, aripiprazole 4.7 ± 1.7; χ2 = 7.7, P < 0.05, df = 2)
after administration compared to controls. All drugs failed to
affect CAR behavior after 24 h.
Neuronal Fos induction
2-Bromoterguride increased Fos levels in the striatum and
mPFC, whereas haloperidol induced an enhancement of Fos
expression only in the striatum (Fig. 2). One-way ANOVA
revealed significant treatment effects in the mPFC
(F(3,28) = 6.8; P < 0.001), NAc (F(3,26) = 5.6; P = 0.004), and
dStr (F(3,27) = 5.8; P < 0.003). 2-Bromoterguride (0.1 and
0.3 mg/kg) enhanced Fos expression both in the mPFC
(P < 0.05) and NAc (P < 0.01). In the dStr, only the lower dose
of 2-bromoterguride induced an increase of the Fos level
(P < 0.05). Haloperidol increased neuronal activity in the
NAc and dStr (P < 0.05), but not in the mPFC (Fig. 2).
Antagonism of DOI-induced wet dog shakes
2-Bromoterguride attenuated DOI-induced wet dog shakes
(Table 1). One-way ANOVA revealed significant treatment
effects in wet dog shaking behavior (F(5,53) = 10.8;
P < 0.001). DOI (5-HT2A/2C receptor agonist) induced a ro-
bust increase in wet dog shakes (P < 0.001). Pretreatment with
ketanserin (5-HT2A receptor antagonist) suppressed the effect
of DOI to vehicle level (P < 0.001). 2-Bromoterguride (0.1
and 0.3 mg/kg) also reduced DOI-induced wet dog shakes
(P < 0.05); however, the effect was different from vehicle
(P < 0.05). Unlike 2-bromoterguride, the reduction of the
DOI effect by aripiprazole was not significant, although it
was significant versus vehicle (P < 0.05; Table 1).
Body weight development, body fat composition, food
intake, locomotor activity, and cataleptic behavior
2-Bromoterguride did not affect body weight, body fat com-
position, or food intake. Body weight development: main ef-
fects for the factors treatment (F(3,651) = 4.8, P = 0.008), time
(F(21,651) = 196.5, P < 0.001), and for the interaction of the
factors (F(63,651) = 1.8, P < 0.001) were observed. Olanzapine
(2 mg/kg) increased body weight (days 6–11, 13–15, 18–21;
P < 0.05), whereas 2-bromoterguride (0.1 and 0.3 mg/kg) did
not (Fig. 3). Body fat composition: olanzapine (2 mg/kg) in-
creased the amount of visceral (F(3,31) = 6.3; P = 0.002) and



































Fig. 2 Effects of 2-bromoterguride (0.1 and 0.3 mg/kg) or haloperidol
(0.5 mg/kg) on Fos protein expression in the nucleus accumbens (NAc),
dorsal striatum (dStr), and medial prefrontal cortex (mPFC). Data are
expressed as mean ± SEM of 8 male rats each treatment group.
*P < 0.05 vs. vehicle. 2-BT 2-bromoterguride, HAL haloperidol, VEH
vehicle
Table 1 Effects of ketanserin (1 mg/kg), 2-bromoterguride (0.1 and
0.3 mg/kg), or aripiprazole (3 mg/kg) on the number of DOI (2 mg/kg)-
induced wet dog shakes
Treatment Number of wet dog shakes
VEH +VEH 0.60 ± 0.43
VEH +DOI (2 mg/kg) 13.00 ± 2.00*
KET (1 mg/kg) + DOI (2 mg/kg) 0.38 ± 0.18#
2-BT (0.1 mg/kg) + DOI (2 mg/kg) 7.18 ± 1.35#
2-BT (0.3 mg/kg) + DOI (2 mg/kg) 6.64 ± 1.88#
ARI (3 mg/kg) + DOI (2 mg/kg) 8.38 ± 1.13*
Data are expressed as mean ± SEM of 11 (2-bromoterguride, DOI), 10
(vehicle), or 8 male rats (aripiprazole, ketanserin)
2-BT 2-bromoterguride, ARI aripiprazole, KET ketanserin, VEH vehicle
*P < 0.05 vs. vehicle; #P < 0.05 vs. DOI
Fig. 3 Effects of 2-bromoterguride (0.1 and 0.3 mg/kg) or olanzapine
(2 mg/kg) on percentage weight gain in female rats treated for 21 days
B.I.D. Data are expressed as mean ± SEM of 9 (2-bromoterguride,
vehicle) or 8 rats (olanzapine). *P < 0.05 vs. vehicle. 2-BT 2-
bromoterguride, OLZ olanzapine, VEH vehicle
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controls (P < 0.01). 2-Bromoterguride did not affect fat tissues
(Table 2). Food intake: statistical analysis revealed main ef-
fects for the factors treatment (F(3,651) = 5.8, P = 0.003), time
(F(21,651) = 14.1, P < 0.001), and for the interaction of the fac-
tors (F(63,651) = 3.4, P < 0.001). Animals treated with
olanzapine (2 mg/kg) had a higher food intake (days 2–10;
P < 0.05), whereas rats treated with 2-bromoterguride showed
no difference compared to controls (P > 0.05; data not shown).
Water intake: main effects for the factors treatment
(F(3,651) = 49.7, P < 0.001), time (F(21,651) = 12.9, P < 0.001),
and for the interaction of the factors (F(63,651) = 2.9, P < 0.001)
were observed. 2-Bromoterguride decreased (days 1–21;
P < 0.001), whereas olanzapine (2 mg/kg) increased water
consumption (days 1–3, 5–6, 9–21; P < 0.05) (data not
shown). Locomotor activity and cataleptic behavior: locomo-
tor activity was affected (F(3,31) = 9.5; P < 0.001). Rats treated
with 2-bromoterguride (0.3 mg/kg) and olanzapine traveled a
shorter distance compared to controls (P < 0.05) (Fig. 4). No
treatment effects were detected in the bar and grid test.
Discussion
The present study further demonstrates that 2-bromoterguride,
a drug with partial agonist effects at D2 receptors, high affinity
for 5-HT2A and α2C-adrenergic but low affinity for histamine
H1 receptors (Jantschak et al. 2013), has antipsychotic prop-
erties without inducing weight gain. In our previous study, we
investigated the antidopaminergic efficacy of 2-
bromoterguride using AIL, and EPS liability using catalepsy
tests (Jantschak et al. 2013). The CAR provides a further
highly predictive and reliable screening tool to test potential
drugs exhibiting antipsychotic-like properties (Wadenberg
2010). It has been shown that well-established APDs, within
a certain dose range, effectively suppress CAR without induc-
ing escape failures. The incidence of escape failures at a given
dose indicates that this dose produces non-specific behavioral
effects such as sedation (Wadenberg 2010). Effective suppres-
sion of CAR with typical and atypical APDs in rats can be
achieved by a striatal D2 receptor occupancy (D2RO) of 65–
80 % (for aripiprazole a D2RO of >85 % was required to
inhibit CAR). These D2ROs reflect the range in which schizo-
phrenic patients respond to APDs (Natesan et al. 2006;
Wadenberg et al. 2001; Wadenberg 2010). The present study
shows that 2-bromoterguride, haloperidol, and aripiprazole
produced a suppression of CAR in a comparable and dose-
dependent manner. Only the high dose of aripiprazole induced
more escape failures than vehicle. This may be related to the
relatively high affinity of aripiprazole for H1 receptors; halo-
peridol and 2-bromoterguride exhibit low affinities for these
receptors (Jantschak et al. 2013; Kroeze et al. 2003). It should
be noted that other receptors than the D2 receptor maymediate
or contribute to the suppression of CAR by 2-bromoterguride.
For example, a blockade of 5-HT2A receptors may be involved
in the disruptive effect on CAR (Wadenberg et al. 1998).
Consistent with this hypothesis, the acute effect of clozapine
on avoidance responding was reversed by DOI (Li et al.
2012). Although DOI is non-selective for 5-HT2A versus 5-
HT2C receptors, the former receptor population can be favored
to be involved in drug-induced disruption on CAR
(Halberstadt et al. 2009; Li et al. 2010, 2012; Schreiber et al.
1995; Sipes and Geyer 1995; Smith et al. 2003). In contrast to
the effect of clozapine, the inability of DOI to reverse CAR
disruption by olanzapine was explained by a predominant
Table 2 Effects of 2-
bromoterguride (0.1 and
0.3 mg/kg) or olanzapine
(2 mg/kg) on visceral,
subcutaneous, and brown fat
tissue in female rats treated for
21 days B.I.D.
Treatment Visceral fat tissue Subcutaneous fat tissue Brown fat tissue
VEH 2.24 ± 0.20 1.09 ± 0.07 0.08 ± 0.008
2-BT (0.1 mg/kg) 2.14 ± 0.17 1.10 ± 0.05 0.09 ± 0.009
2-BT (0.3 mg/kg) 2.02 ± 0.11 1.10 ± 0.04 0.06 ± 0.005
OLZ (2 mg/kg) 2.93 ± 0.14* 1.61 ± 0.13* 0.08 ± 0.004
Tissue weights were calculated in relation to body weight (g/100 g bw). Data are expressed as mean ± SEM of 9
(2-bromoterguride, vehicle) or 8 rats (olanzapine)
2-BT 2-bromoterguride, OLZ olanzapine, VEH vehicle


































Fig. 4 Effects of 2-bromoterguride (0.1 and 0.3 mg/kg) or olanzapine
(2 mg/kg) on spontaneous locomotion plotted as total distance traveled in
30 min. Data are expressed as mean ± SEM of 9 (2-bromoterguride,
vehicle) or 8 rats (olanzapine). *P < 0.05 vs. vehicle. 2-BT 2-
bromoterguride, OLZ olanzapine, VEH vehicle
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involvement of D2 receptors in this response (Li et al. 2012).
This is because olanzapine has a much higher D2 receptor
affinity than clozapine, whereas both drugs display similar
affinity for 5-HT2A receptors (Kroeze et al. 2003). 2-
Bromoterguride exhibits high affinity for both D2 and 5-
HT2A receptors; therefore, it is difficult to decide which recep-
tor is predominantly responsible for the inhibition of CAR by
this drug. α2-Adrenoceptor blockade may also contribute to
the effect of 2-bromoterguride on CAR. Pretreatment with
idazoxan (α2-adrenoceptor antagonist) enhanced the antipsy-
chotic effects of typical and atypical APDs, as, for example,
demonstrated in the CAR test (Marcus et al. 2010). Because 2-
bromoterguride exhibited high affinity for D2, 5-HT2A, and
α2C-adrenoceptors, all of these properties may be associated
with its ability to suppress CAR, thus highlighting the
antipsychotic-like potential of this drug.
APDs induce the expression of the immediate-early gene
product Fos in a distinct pattern of brain regions, which is
suggested as an indicator of antipsychotic efficacy
(Dragunow et al. 1990; Miller 1990; Robertson et al. 1994;
Natesan et al. 2011). In addition, expression of Fos in the
mPFC can be used to identify atypical APDs (Robertson and
Fibiger 1996). For example, acute administration of haloper-
idol increased Fos expression in the dStr and the NAc but not
in the mPFC (Young et al. 1999; this study). In contrast, clo-
zapine and other atypical APDs enhanced Fos protein in the
NAc and mPFC but not in the dStr (Deutch et al. 1992; Dilts
et al. 1993; Nguyen et al. 1992; Robertson et al. 1994;
Robertson and Fibiger 1996). In this context, it was of special
interest to find out whether 2-bromoterguride, a low-efficacy
D2 receptor partial agonist, might enhance Fos in different
brain regions. As suggested by Natesan et al. (2011), a crite-
rion for therapeutic success of novel APDs may be their po-
tential to exhibit low intrinsic activity coupled with sufficient
D2 receptor functional antagonism. Among several preclinical
tests, Natesan et al. (2011) favored Fos expression in the NAc
as a marker of overall functional antagonism and thus high
predictive validity. 2-Bromoterguride increased Fos expres-
sion in the NAc, the dStr, and the mPFC as well. This means
that 2-bromoterguride mimics haloperidol as an enhancer of
Fos in the NAc and the dStr, and clozapine in the NAc and the
mPFC. Positive symptoms of schizophrenia are related to an
excess of dopamine in the NAc, whereas a lack of dopamine
in the dorsolateral PFC is essential for negative symptoms and
cognitive deficits (Abi-Dargham 2004). The increase of Fos in
the NAc and the mPFC in rats by 2-bromoterguride suggests
that this drug may possess the beneficial antipsychotic prop-
erties of both haloperidol and clozapine and thus may contrib-
ute to improve treatment outcome. Admittedly, this suggestion
is rather speculative and further studies are needed to substan-
tiate the findings of our study. Anyway, particularly the in-
crease of Fos in the mPFC by 2-bromoterguride indicates that
this drug may have the antipsychotic properties of an atypical
APD with respect to actions on negative symptoms and cog-
nitive deficits in schizophrenia (Robertson et al. 1994;
Robertson and Fibiger 1996).
Wet dog shakes are behavioral effects in rodents which are
amenable to inhibition by a large number of 5-HT receptor
antagonists including APDs (Porsolt et al. 2010). The wet dog
shake response is induced by selective activation of central 5-
HT2A receptors (Schreiber et al. 1995). 5-HT2A receptor in-
verse agonist/antagonist activity is a characteristic feature of
atypical APDs (Meltzer et al. 2012). The high in vitro affinity
for 5-HT2A receptors is in line with the effectiveness of 2-
bromoterguride to reduce DOI-induced wet dog shakes in rats.
In contrast to the reduction of DOI-induced wet dog shakes by
2-bromoterguride (0.1 and 0.3 mg/kg), the decrease by
aripiprazole (3 mg/kg) was not significant. It should be em-
phasized that aripiprazole attenuated DOI-induced wet dog
shakes when high doses were used (10–30 mg/kg; Kohnomi
et al. 2008), reflecting the low affinity of aripiprazole for 5-
HT2A receptors. Indeed, 5-HT2A receptor affinity of
aripiprazole was 50-fold lower than that of 2-bromoterguride
(Jantschak et al. 2013). The difference between ketanserin and
2-bromoterguride as inhibitors of DOI-induced wet dog
shakes needs a comprehensive consideration. Although both
compounds exhibited similar 5-HT2A receptor affinity,
ketanserin reduced the DOI response to vehicle level, whereas
2-bromoterguride did not. A possible explanation for this dis-
crepancy may be that ketanserin is a competitive 5-HT2A re-
ceptor antagonist in contrast to 2-bromoterguride which be-
haves as an insurmountable antagonist (Jantschak et al. 2013).
Moreover, terguride, the parent drug of 2-bromoterguride, was
a partial agonist at 5-HT2A receptors in a GTPγS binding
assay (Newman-Tancredi et al. 2002). It cannot be excluded
that 2-bromoterguride is acting as a partial agonist at 5-HT2A
receptors. Furthermore, 2-bromoterguride displayed
subnanomolar affinity for α2C-adrenoceptors (Jantschak
et al. 2013). Interestingly, α2-adrenoceptor antagonists re-
versed the suppression of head-twitch behavior by 5-HT2A
receptor antagonists (Matsumoto et al. 1997). In addition, 2-
bromoterguride may modulate AMPA/kainate receptors.
Indeed, blockade of AMPA/kainate receptors attenuated
DOI-induced wet dog shakes (Gorzalka et al. 2005).
Clinically significant weight gain is a serious side effect of
atypical APDs (Correll et al. 2011 for review; Parsons et al.
2009) and characterized by a substantial increase in food con-
sumption and visceral and subcutaneous fat deposition (Zhang
et al. 2004). A recent meta-analysis showed that haloperidol,
ziprasidone, and lurasidone were the only APDs without af-
fecting body weight in adults (Leucht et al. 2013). Since
olanzapine induced more weight gain than any other APD in
preclinical and clinical studies (Allison et al. 1999; Davey
et al. 2012; Leucht et al. 2013), we used this drug as a positive
control. Olanzapine-induced weight gain, food consumption
as well as visceral and subcutaneous fat tissue weights in rats
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are consistent with observations of other groups (Choi et al.
2007; Davey et al. 2012; Mann et al. 2013). The mechanism
by which olanzapine and other APDs induce weight gain is
likely multifactorial and not completely understood. It has
been suggested that 5-HT2C and H1 receptors, for which
olanzapine and clozapine display high affinity, are strong can-
didate receptors for affecting appetite and thereby weight gain
(Deng et al. 2010; Kirk et al. 2009; Kroeze et al. 2003). In
addition, association of a polymorphism of the 5-HT2C recep-
tor gene with APD-induced weight gain highlights the role of
this receptor in this metabolic side effect (Reynolds et al.
2002). However, mechanisms other than those mentioned
above, e.g., D2 receptor gene polymorphism, may also be
associated with APD-induced weight gain (Müller et al.
2012).
In contrast to the effect of olanzapine, chronic treatment of
rats with 2-bromoterguride failed to elicit an effect on body
weight and body fat proportion. The low affinity of 2-
bromoterguride for H1 receptors (pA2 6.0; Jantschak et al.
2013) may be responsible for the non-occurrence of this side
effect in the treatment with this drug. Unfortunately, there are
no data available with regard to the affinity of 2-
bromoterguride for 5-HT2C receptors. However, terguride,
the parent drug of 2-bromoterguride, exhibited low affinity
for this receptor (pKB 6.1; Newman-Tancredi et al. 2002).
The absence of any effect of 2-bromoterguride on body
weight, food consumption, and visceral and subcutaneous
fat tissue weights suggests that 5-HT2C receptors have no
functional relevance in the side effect profile of this drug.
Further, chronic treatment with 2-bromoterguride decreased
locomotor activity but failed to induce catalepsy. This is con-
sistent with the effect of acute 2-bromoterguride treatment
(Jantschak et al. 2013) and other D2 receptor partial agonists
(Natesan et al. 2011; Nordquist et al. 2008; Svensson et al.
1991). The sedative effect of 2-bromoterguride is probably
mediated by the dopaminergic system as the low affinity for
the H1 receptor argues against an involvement of this receptor
in the inhibitory action on locomotor activity.
In conclusion, our in vivo studies show that 2-
bromoterguride is effective in tests for positive symptoms of
schizophrenia. In addition, 5-HT2A receptor blockade by 2-
bromoterguride has functional relevance in vivo and the in-
duced Fos protein expression in the NAc and mPFC suggests
an atypical character. Chronic treatment failed to alter meta-
bolic parameters which are often associated with atypical
APDs. 2-Bromoterguride, a drug with partial agonist effects
at D2 receptors and high affinity for 5-HT2A and α2C-adren-
ergic receptors, is a promising candidate for antipsychotic
treatment. Further preclinical behavioral studies predicting an-
tipsychotic effects are needed to verify 2-bromoterguride as an
atypical APD, in particular experiments with relevance to cog-
nitive impairment and negative symptoms present in
schizophrenia.
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